Drug Profile
JNJ 39393406
Alternative Names: JNJ-39393406Latest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica
- Developer Janssen Pharmaceutica; National Institutes of Health (USA); University of Pittsburgh
- Class Antidementias; Nootropics
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Depressive disorders; Schizophrenia; Smoking withdrawal
Most Recent Events
- 08 Sep 2021 Discontinued - Phase-II for Depressive disorders in Moldova and Romania (PO) before September 2021 (Johnson & Johnson Pharmaceutical Research & Development's pipeline, September 2021)
- 08 Sep 2021 Discontinued - Phase-II for Smoking withdrawal in USA (PO) before September 2021 (Johnson & Johnson Pharmaceutical Research & Development's pipeline, September 2021)
- 15 Feb 2016 Johnson & Johnson Pharmaceutical Research plans the exploratory phase II JNJ-DEP trial for Depressive disorders in Romania (PO, Capsule) (NCT02677207)